DHEA for Women: Benefits, Risks, and What the Research Actually Says

DHEA — dehydroepiandrosterone — is the most abundant steroid hormone in the human body, yet it's one of the least discussed in conventional medicine. Produced primarily by the adrenal glands, DHEA is a precursor hormone that the body converts into estrogens, testosterone, and other androgens. Its levels peak in the mid-20s and decline steadily with age — by age 70, most people have only 10–20% of their peak DHEA levels. This dramatic age-related decline has made DHEA a subject of intense interest in longevity and hormonal optimization medicine.

What DHEA Does in the Female Body

In women, DHEA plays a particularly multifaceted role. Unlike men, who rely primarily on the testes for testosterone production, women produce most of their androgens (including testosterone) through DHEA conversion in peripheral tissues. The skin, brain, liver, adipose tissue, and reproductive organs all convert DHEA locally into androgens and estrogens in a process called "intracrinology" — enabling tissue-specific hormonal signaling without the systemic effects of circulating sex hormones.

DHEA influences:

• Energy and vitality: DHEA supports mitochondrial function and overall cellular energy production
• Libido and sexual function: Testosterone derived from DHEA is the primary driver of female sexual desire
• Mood and cognitive function: DHEA has neuroactive properties, influencing GABA receptors and serotonergic pathways
• Bone density: DHEA-derived androgens help maintain bone mass and reduce fracture risk
• Immune regulation: DHEA modulates immune function, generally promoting a more balanced immune response
• Skin health: Local DHEA conversion in skin supports collagen production and skin thickness
• Vaginal health: Vaginal DHEA (prasterone) is FDA-approved for treating genitourinary syndrome of menopause

Evidence-Based Benefits of DHEA for Women

Sexual Function and Genitourinary Health

The strongest evidence for DHEA in women involves sexual function and genitourinary health. A major randomized controlled trial (the DHEA-6 trial) demonstrated that oral DHEA supplementation in postmenopausal women significantly improved sexual desire, arousal, lubrication, orgasm, and reduced sexual pain — all domains of sexual function — compared to placebo. Intravaginal DHEA (prasterone) received FDA approval in 2016 for treating dyspareunia (painful intercourse) associated with menopause, making it the only FDA-approved DHEA product for women.

Mechanism: DHEA converts locally in vaginal tissues to estradiol and testosterone, which restore mucosal thickness, lubrication, and nerve sensitivity — reversing the atrophic changes of estrogen deficiency without substantially raising systemic hormone levels.

Bone Density and Fracture Risk

Several studies have found that higher DHEA-S levels (DHEA-sulfate, the main circulating form) are associated with greater bone mineral density in postmenopausal women. DHEA supplementation studies have shown modest but significant improvements in lumbar spine and femoral neck bone density, particularly in women with low baseline DHEA-S levels. This makes DHEA an interesting adjunctive strategy for osteoporosis prevention, though it should not replace established therapies like bisphosphonates or estrogen when clearly indicated.

Risks and Considerations for Women

DHEA is not without potential risks, and its use requires careful medical oversight:

• Androgenic side effects: In susceptible women, excessive DHEA conversion to androgens can cause acne, oily skin, facial hair, and voice changes. These effects are dose-dependent and reversible.
• Hormone-sensitive conditions: Women with hormone-sensitive cancers (breast, ovarian, uterine) should generally avoid systemic DHEA unless under careful oncological supervision.
• PCOS: Women with polycystic ovary syndrome already tend to have higher androgen levels; DHEA supplementation may worsen androgenic symptoms.
• Variable conversion: DHEA conversion efficiency varies significantly between individuals based on genetics, body composition, and enzyme activity, making dosing unpredictable without monitoring.
• OTC availability concerns: DHEA is sold over-the-counter in the US, often in doses (25–50mg) higher than many clinicians would recommend as a starting point. Self-supplementation without testing and monitoring is inadvisable.

Testing and Optimization: The Right Approach

Before considering DHEA supplementation, baseline DHEA-S levels should be measured via blood test. DHEA-S is the sulfated, stable form of DHEA and provides the most accurate picture of adrenal androgen status. Levels below 100–150 µg/dL in women under 50 or below 70–100 µg/dL in women over 50 may warrant consideration of supplementation.

DHEA therapy should be started at low doses (5–10mg orally or topically) with follow-up testing at 6–12 weeks to assess response and adjust dosing. Because DHEA is a precursor, monitoring should include not just DHEA-S but also testosterone, estradiol, and SHBG to assess conversion patterns and ensure appropriate hormonal balance.

DHEA is one component of a comprehensive women's hormonal optimization strategy. Learn more about women's hormones and explore our HRT guide for menopause to understand how DHEA fits within a broader hormonal picture. Our telehealth providers can evaluate your complete hormonal profile and determine whether DHEA optimization is appropriate for your specific situation.

DHEA and Cognitive Function: What the Research Suggests

One of the emerging areas of interest in DHEA research is its potential role in cognitive aging and brain health. The brain is rich in DHEA and its sulfate form (DHEA-S), and these neurosteroids appear to modulate GABA-A and NMDA receptors, influence neuroplasticity, and protect against oxidative stress and neuroinflammation. Several observational studies have found correlations between higher DHEA-S levels and better cognitive performance in older adults.

Intervention studies have produced mixed results — some showing modest improvements in memory and executive function with DHEA supplementation, others showing no significant cognitive benefit. The variability likely reflects differences in baseline DHEA-S levels, age of subjects, dosing, and duration. The most robust cognitive effects have been observed in individuals with low baseline DHEA-S, suggesting that replacement to physiological levels — rather than supplementation in those already sufficient — is most likely to produce benefit. This reinforces the importance of testing before treatment: supplementing DHEA without knowing your baseline level is both scientifically unjustified and potentially risky.